MX2007007610A - Regimen de cladribina para tratar esclerosis multiple. - Google Patents

Regimen de cladribina para tratar esclerosis multiple.

Info

Publication number
MX2007007610A
MX2007007610A MX2007007610A MX2007007610A MX2007007610A MX 2007007610 A MX2007007610 A MX 2007007610A MX 2007007610 A MX2007007610 A MX 2007007610A MX 2007007610 A MX2007007610 A MX 2007007610A MX 2007007610 A MX2007007610 A MX 2007007610A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
treating multiple
cladribine
regimen
cladribine regimen
Prior art date
Application number
MX2007007610A
Other languages
English (en)
Spanish (es)
Inventor
Luca Giampiero De
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007007610(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Serono Lab filed Critical Serono Lab
Publication of MX2007007610A publication Critical patent/MX2007007610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2007007610A 2004-12-22 2005-12-20 Regimen de cladribina para tratar esclerosis multiple. MX2007007610A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2007007610A true MX2007007610A (es) 2007-08-03

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007610A MX2007007610A (es) 2004-12-22 2005-12-20 Regimen de cladribina para tratar esclerosis multiple.

Country Status (25)

Country Link
US (2) US7713947B2 (https=)
EP (7) EP3332789B1 (https=)
JP (7) JP5795456B2 (https=)
KR (1) KR20070091662A (https=)
AR (1) AR052830A1 (https=)
AU (2) AU2005318190B2 (https=)
BR (1) BRPI0517132B8 (https=)
CA (2) CA3087419C (https=)
CY (3) CY1112614T1 (https=)
DK (3) DK3332789T3 (https=)
EA (1) EA015799B1 (https=)
ES (2) ES3007339T3 (https=)
FI (1) FI4070800T3 (https=)
FR (1) FR18C1008I2 (https=)
HR (1) HRP20120228T1 (https=)
HU (3) HUE059133T2 (https=)
IL (2) IL183930A0 (https=)
LT (3) LT3332789T (https=)
LU (1) LUC00064I2 (https=)
MX (1) MX2007007610A (https=)
NO (1) NO20073813L (https=)
PL (4) PL3332789T3 (https=)
SG (1) SG160391A1 (https=)
SI (3) SI4070800T1 (https=)
WO (1) WO2006067141A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3332789B1 (en) 2004-12-22 2022-04-06 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
EP3713582A1 (en) * 2017-11-24 2020-09-30 Merck Patent GmbH Cladribine regimen for use intreating progressive forms of multiple sclerosis
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
ES2182920T3 (es) 1994-12-22 2003-03-16 Ortho Pharma Corp Formulaciones solubles de 2-cloro02'-deoxiadenosina.
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
ES2405825T3 (es) 2002-09-25 2013-06-03 Brigham Young University Método para la preparación de compuestos 2-halo-2'-desoxiadenosina a partir de 2'-desoxiguanosina
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2004216485B2 (en) * 2003-02-25 2009-06-11 Merck Serono Sa Combined use of ribavirin and interferon beta in demyelinating diseases
HRP20050924A2 (en) 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
ES2409884T3 (es) * 2003-03-28 2013-06-28 Ares Trading S.A. Formulaciones orales de cladribina
EP3332789B1 (en) 2004-12-22 2022-04-06 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
LT3332789T (lt) 2022-07-25
CA3087419C (en) 2023-03-07
LTPA2018503I1 (lt) 2018-03-12
ES2921858T3 (es) 2022-09-01
EP2275110B1 (en) 2013-07-10
EA015799B1 (ru) 2011-12-30
EP4070800A1 (en) 2022-10-12
EP2805723B1 (en) 2018-01-17
EP2263678A2 (en) 2010-12-22
LTC2805723I2 (lt) 2022-04-25
BRPI0517132A (pt) 2008-09-30
FR18C1008I1 (https=) 2018-03-30
IL212421A (en) 2014-01-30
CA3087419A1 (en) 2006-06-29
EP3332789B1 (en) 2022-04-06
SG160391A1 (en) 2010-04-29
BRPI0517132B1 (pt) 2020-02-18
WO2006067141A1 (en) 2006-06-29
LT4070800T (lt) 2025-01-10
PL3332789T3 (pl) 2022-08-22
JP2015180685A (ja) 2015-10-15
JP6290962B2 (ja) 2018-03-07
JP6092945B2 (ja) 2017-03-08
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
JP2020193206A (ja) 2020-12-03
HRP20120228T1 (hr) 2012-04-30
KR20070091662A (ko) 2007-09-11
SI4070800T1 (sl) 2025-03-31
AR052830A1 (es) 2007-04-04
HUE070333T2 (hu) 2025-05-28
AU2011200768B2 (en) 2012-09-13
IL212421A0 (en) 2011-06-30
SI2805723T1 (en) 2018-02-28
JP5908863B2 (ja) 2016-04-26
US20090081163A1 (en) 2009-03-26
FI4070800T3 (fi) 2025-01-14
PL1827461T3 (pl) 2012-07-31
SI3332789T1 (sl) 2022-08-31
EA200701221A1 (ru) 2008-02-28
ES3007339T3 (en) 2025-03-19
US8377903B2 (en) 2013-02-19
EP3332789A1 (en) 2018-06-13
EP2263678B1 (en) 2014-06-11
CY1112614T1 (el) 2016-02-10
AU2011200768A1 (en) 2011-03-17
JP2013216664A (ja) 2013-10-24
AU2005318190B2 (en) 2010-11-25
EP2805723A1 (en) 2014-11-26
PL2805723T3 (pl) 2018-04-30
EP4523753A2 (en) 2025-03-19
CA2588966A1 (en) 2006-06-29
FR18C1008I2 (fr) 2019-03-01
JP5795456B2 (ja) 2015-10-14
HUS1800009I1 (hu) 2018-05-02
IL183930A0 (en) 2007-10-31
EP4523753A3 (en) 2025-05-28
HUE059133T2 (hu) 2022-10-28
EP2275110A3 (en) 2011-04-27
CY2018006I2 (el) 2018-06-27
JP2008524313A (ja) 2008-07-10
CY2018006I1 (el) 2018-06-27
PL4070800T3 (pl) 2025-03-10
CA2588966C (en) 2020-07-21
JP2017101061A (ja) 2017-06-08
EP1827461A1 (en) 2007-09-05
CY1119790T1 (el) 2018-06-27
AU2005318190A1 (en) 2006-06-29
LUC00064I2 (https=) 2018-03-28
EP2263678A3 (en) 2011-04-27
DK2805723T3 (da) 2018-01-29
US20100203017A1 (en) 2010-08-12
JP2018165271A (ja) 2018-10-25
LUC00064I1 (https=) 2018-02-14
JP6430554B2 (ja) 2018-11-28
JP2016138128A (ja) 2016-08-04
US7713947B2 (en) 2010-05-11
BRPI0517132B8 (pt) 2021-05-25
NO20073813L (no) 2007-09-21
EP4070800B1 (en) 2024-10-16
EP2275110A2 (en) 2011-01-19
EP1827461B1 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CR9348A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
UY27740A1 (es) Nuevos compuestos
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
MX2007009032A (es) Formulacion para inyeccion de butanos catecolicos incluyendo compuestos ndga en animales.
AR109263A2 (es) Composición que comprende moxidectina
ECSP088889A (es) Forma nueva de administración de racecadotril
MX2007007610A (es) Regimen de cladribina para tratar esclerosis multiple.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
BR112012014159A2 (pt) Combinações terapêuticas de teobromina e um anti-histamínico
CO6470875A2 (es) Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: TETRA LAVAL HOLDING & FINANCE S.A.